Pfizer’s Bivalent rLP2086 Receives FDA Breakthrough Therapy Designation for Potential Prevention of Meningococcal B

Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease Pfizer Intends to Submit Biologics License Application for Bivalent rLP2086 to U.S. Food and Drug Administration by Mid-2014 March 20, 2014 Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation …